Evidence-Based Medicine Guidelines
Neuroleptic malignant syndrome (NMS)
Neuroleptic malignant syndrome (NMS) is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Neuroleptic Malignant Syndrome (NMS)." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454986/all/Neuroleptic_malignant_syndrome__NMS_.
Neuroleptic malignant syndrome (NMS). Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/454986/all/Neuroleptic_malignant_syndrome__NMS_. Accessed March 24, 2023.
Neuroleptic malignant syndrome (NMS). (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/454986/all/Neuroleptic_malignant_syndrome__NMS_
Neuroleptic Malignant Syndrome (NMS) [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454986/all/Neuroleptic_malignant_syndrome__NMS_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Neuroleptic malignant syndrome (NMS)
ID - 454986
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454986/all/Neuroleptic_malignant_syndrome__NMS_
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
